Guglin Maya, Cutro Raymond, Mishkin Joseph D
University of South Florida, Tampa, Florida, USA.
J Card Fail. 2008 Jun;14(5):437-44. doi: 10.1016/j.cardfail.2008.02.002.
Trastuzumab is a recombinant humanized monoclonal antibody used for the treatment of advanced breast cancer. It improves survival and increases response to chemotherapy. The major side effect of trastuzumab is cardiotoxicity manifesting as a reduction in left ventricular systolic function, either asymptomatic or with signs and symptoms of heart failure. Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab. The objective of this review is to summarize facts about trastuzumab-induced cardiotoxicity and to highlight the areas of future investigations. We searched PubMed for trials involving trastuzumab used as an adjuvant therapy for breast cancer, including the metastatic breast cancer setting, and focused on cardiotoxicity.
曲妥珠单抗是一种重组人源化单克隆抗体，用于治疗晚期乳腺癌。它可提高生存率并增强对化疗的反应。曲妥珠单抗的主要副作用是心脏毒性，表现为左心室收缩功能降低，可为无症状性或伴有心力衰竭的体征和症状。尽管在大多数情况下心脏毒性是可逆的，但它经常导致曲妥珠单抗停药。本综述的目的是总结曲妥珠单抗所致心脏毒性的相关事实，并突出未来研究的领域。我们在PubMed上搜索了涉及曲妥珠单抗用作乳腺癌辅助治疗（包括转移性乳腺癌情况）的试验，并重点关注心脏毒性。
